<DOC>
	<DOCNO>NCT00352378</DOCNO>
	<brief_summary>This open label phase III randomize trial . The patient clinical stage II III undergo mammotome biopsy breast tumor histologic diagnosis , immunohistochemical study estrogen receptor ( ER ) , progesterone receptor ( PR ) , HER-2/neu others . PET result determine positivity lymph node metastasis .</brief_summary>
	<brief_title>Primary Chemotherapy With Adriamycin/Cyclophosphamide ( AC ) v Taxotere/Xeloda ( TX ) Stage II III Breast Cancer</brief_title>
	<detailed_description>- Patients randomized receive regimen A ( AC ) regimen B ( TX ) , preoperatively , follow : Regimen A ( AC ) : Intravenous infusion Adriamycin 60mg/m2 , 30 min , onD1 Intravenous infusion cyclophosphamide 600 mg/m2 30 min D1 . Regimen B ( TX ) : Intravenous infusion Taxotere 75 mg/m2 1 hr , D1 , Xeloda 1000mg/m2.p.o . BID x 14days D1-D14 The cycle repeat every 3 week 4 time . Premedication regimen A include antiemetic , regimen B , dexamethasone routinely give . Patients respond initial two cycle preoperative chemotherapy undergo operation . The response rate determine number patient complete partial response accord RECIST guideline . Pathologic complete response define pathologic evidence residual disease . Safety evaluate frequency , severity , relationship adverse event grade NCI Common Toxicity Criteria ( CTC ) occur treatment follow-up period . Time disease progression calculate date study entry first objective documentation progressive disease . Response duration measure date patient first fulfill CR PR criterion first date objective documentation disease progression . Survival time calculate date study entry date death</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>All patient must histologically confirm newly diagnose breast cancer : stage II III breast cancer . PET result determine node positivity . No prior hormonal , chemotherapy radiotherapy allow . No breast operation biopsy make diagnosis allow . Age:18years old , pregnant pre , postmenopausal woman good performance status ( ECOG 01 ) Adequate hematopoietic function : 1 . Absolute granulocyte count &gt; =1500/mm3 , 2. platelet &gt; =100,000/mm3 , Hemoglobin &gt; =10 g/mm3 Adequate renal function : Serum creatinine &lt; =1.5 mg/dl Adequate hepatic function : 1. total bilirubin : &lt; =1.5 mg/dl 2 . AST/ALT : &lt; =three time normal 3 . Alkaline phosphatase : &lt; =three time normal Adequate cardiac function : normal nonspecific EKG take within 1 mo enrollment Patients receive hormonal , chemotherapy radiotherapy breast cancer Patients underwent surgery breast cancer Patients history cancer situ uterine cervix cancer nonmelanotic skin cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Primary</keyword>
</DOC>